Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2010

CHDI Pledges $37.5M in Research Funding Over the Next Three Years to Evotec

  • Evotec and the CHDI Foundation extended their Huntington disease therapeutics collaboration through to the end of 2012. The extension will provide Evotec with up to $37.5 million in research funding over the next three years.

    The organizations initiated their Huntington-focused partnership in March 2006 and have since signed four agreements covering medicinal chemistry, assay development, and screening along with library synthesis and management services. 

    Evotec is applying its biological science expertise to develop assays such as those designed for high-content screening against high-priority biological targets that are believed to be relevant to the future treatment of Huntington Disease for CHDI and the High Q Foundation.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »